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Abstract: Patients with coronavirus disease 2019 (COVID-19) develop severe respiratory failure
within a short period during the clinical course. It is essential to predict respiratory deterioration
in the short term. We investigated the use of inflammatory markers to predict respiratory distress
within three days from their analysis in COVID-19 patients. This retrospective observational study
included 81 patients admitted with COVID-19. Patients were divided into two groups according
to whether the maximum fraction of inspired oxygen (FiO2) for three days from the blood marker
measurements was ≥0.4 (high FiO2 group; HFG) or <0.4 (low FiO2 group; LFG). Interleukin-6 (IL-6),
C-reactive protein (CRP), lactate dehydrogenase (LDH), white blood cell, D-dimer, and creatinine
levels were compared between the two groups. The levels of all markers were significantly higher
in HFG patients. Areas under the receiver operating characteristic curve of IL-6, CRP, and LDH had
high values of 0.85, 0.82, and 0.81, respectively. The odds ratio of IL-6 which was crude and adjusted
for dexamethasone administration initiated before laboratory measurement, showed the high value of
29.1 (5.6–295.6) and 53.9 (4.5–3242.8), respectively. IL-6 can be used as a reliable marker for predicting
respiratory illness within three days after assessment.
Keywords: inflammatory marker; interleukin-6; novel coronavirus disease; respiratory failure
1. Introduction
Coronavirus disease 2019 (COVID-19) was first reported in Wuhan, China, in Decem-
ber 2019, and WHO declared it a pandemic in January 2020 [1]. This pandemic represents
a global crisis for public health. The clinical manifestations of COVID-19 are wide-ranging,
from asymptomatic to severe viral pneumonia such as acute respiratory distress syndrome
(ARDS). Some COVID-19 patients experience respiratory deterioration over a short period
of time during the clinical course. Thus, it is essential to identify patients who are likely to
develop severe conditions as early as possible. Some studies have demonstrated that sev-
eral blood markers could predict respiratory failure in COVID-19 patients [2,3]. Moreover,
it has been reported that some inflammatory cytokines could distinguish disease severity
in COVID-19 [4]. However, in some patients, the general condition dramatically worsens
within a couple of days with severe respiratory failure. How to predict rapid respiratory
failure remains unknown. Therefore, it is of high priority to identify reliable blood markers
which could predict respiratory illness in the short term in clinical settings. This study
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aimed to investigate the predictive ability of laboratory markers for respiratory failure
within the short term in COVID-19 patients.
2. Materials and Methods
2.1. Patients and Study Design
This single-center, retrospective observational study was approved by the local ethics
committee of Otsu City Hospital (No. 43). A total of 164 patients who tested positive for
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by real-time polymerase
chain reaction (PCR) from the nasopharyngeal swab were admitted to our hospital from
19 October 2020 to 30 April 2021. Data on demographic characteristics, underlying co-
morbidities, details of the treatment, time from symptom onset to admission, and the first
measurement of blood specimens, and outcomes, were collected for all patients in this study.
The laboratory values measured after admission included interleukin-6 (IL-6), C-reactive
protein (CRP), lactate dehydrogenase (LDH), D-dimer, white blood cell (WBC), and crea-
tinine (Cr) levels. Additionally, for 3 days from laboratory measurement, the fraction of
inspired oxygen (FiO2) and the percutaneous oxygen saturation (SpO2) as a respiratory
condition were assessed for all patients. For patients without invasive mechanical ven-
tilation, the conversion of the inspired oxygen (O2) amount [liter (L)/minute (M)] to O2
concentration (FiO2 0.25 to O2 1 L/M, FiO2 0.28 to O2 2 L/M, FiO2 0.32 to O2 3 L/M, FiO2
0.36 to O2 4 L/M, FiO2 0.4 to O2 5 L/M) was used. Furthermore, the maximum FiO2 within
3 days was determined. The supplemental oxygen therapy was initiated when the patients’
SpO2 was less than 94%.
2.2. Laboratory Analysis of Blood Specimens
Serum and plasma samples were separated by centrifugation at 3000 rpm for 5 min.
The levels of IL-6 were measured on a Cobas 8000 specimen form (Roche Diagnostics,
Basel, Switzerland) by electrochemiluminescence immunoassay. LDH, Cr, and CRP levels
were measured using a TBA-FX8 instrument (Canon Medical Systems, Tochigi, Japan) by
an enzymatic reaction for LDH and Cr and latex turbidimetric reaction for CRP. WBC
counts were performed using a DXH 900 hematology analyzer (Beckman Coulter, Tokyo,
Japan). D-dimer levels were determined using a CS2100i automatic coagulation analyzer
(Sysmex, Kobe, Japan) by a latex-enhanced photometric immunoassay.
2.3. Statistical Analysis
Categorical variables were presented as proportions or frequencies (%), and the χ2 test
or Fisher’s exact test was used to compare the prevalence between the 2 groups. Normal
and non-normally distributed continuous variables were presented as mean ± standard
deviation and median (interquartile range) and were analyzed by variance analysis and
Mann–Whitney U-test, respectively. Statistical significance was set at p < 0.05. The pre-
dictive value was evaluated by measuring the area under the curve (AUC). The optimal
cutoff value was obtained by calculating the Youden index. Several cutoff values of each
marker were obtained from different coordinates of the ROC curve to compare the sen-
sitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV)
of these cutoff values. The odds ratio (OR) estimation was performed by using Fisher’s
exact test. The correlation coefficients were obtained by the Spearman correlation analysis.
Statistical analyses were performed using R software package (version 4.0.3, R Core Team.




Among the 164 eligible patients, those lacking laboratory data (n = 74) and those
younger than 18 years (n = 8) were excluded. One patient who received venovenous
extracorporeal membrane oxygenation (ECMO) on the days of evaluation of laboratory
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values and oxygen amount was excluded. A total of 81 adult patients were included
in the study (Figure 1). These patients were divided into a FiO2 ≥ 0.4 group (high FiO2
group (HFG) and a FiO2 < 0.4 group (low FiO2 group; LFG) according to the maximum
FiO2 for three days from the measurement of laboratory markers. A total of 16 patients were
assigned to the HFG group, and 65 patients were allocated to the LFG group (Figure 1).
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Figure 1. Study flow.
Among all patients, 50 patients (61.7%) were male, the mean age was 62.0 ± 16.3 years,
and the mean body mass index (BMI) was 25.0 ± 4.5 kg/m2. There were no significant
differences in sex, age or BMI between the two groups. Th number of comorbiditi s was
significantly higher in the HFG patients. The most com on comorbidity was hypertension
(43.2%; Table 1). Most HFG patien s (81.2%) received i vasive me hanical ventilation,
a d all HFG patients w re prescrib d dexamethasone 6 g daily (Table 1). Although many
patients (65.4%) received favi iravir, any anti-inflammatory or anti-viral drug other than
examethasone and favipiravir was not ad inistered. The median times from symptom
o set to admission and to the first measurement of each rker in the HFG patients were
long r than those in the LFG patients. No significant iffer nc in prognosis was found
betwe n the two groups (Table 1). In th HFG patients, the edian time from ev luating
the laboratory markers to exceeding the maximum FiO2 ≥ 0.4 was 1 (0–2) days.
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Maximum FiO2 ≥ 0.4 p-Value
Yes (n = 16) No (n = 65)
Mean age, y (±SD) 62.0 ± 16.3 68.1 ± 13.9 60.6 ± 16.5 0.090
Male sex, n (%) 50 (61.7%) 12 (75.0%) 38 (58.5%) 0.260
Mean BMI, kg/m2 (±SD) 25.0 ± 4.5 25.7 ± 4.4 24.9 ± 4.5 0.500
Any comorbidities, n (%) 52 (64.2%) 15 (93.8%) 37 (56.9%) 0.007
Hypertension, n (%) 35 (43.2%) 10 (62.5%) 25 (38.5%) 0.100
Coronary artery disease, n (%) 8 (9.9%) 2 (12.5%) 6 (9.2%) 0.650
Diabetes mellitus, n (%) 18 (22.2%) 5 (31.2%) 13 (20.0%) 0.330
Chronic obstructive pulmonary disease, n (%) 7 (8.6%) 2 (12.5%) 5 (7.7%) 0.620
Bronchial asthma, n (%) 6 (7.4%) 0 (0%) 6 (9.2%) 0.590
Sleep apnea syndrome, n (%) 8 (9.9%) 2 (12.5%) 6 (9.2%) 0.650
Chronic kidney disease, n (%) 6 (7.4%) 3 (18.8%) 3 (4.6%) 0.088
Bacterial superinfection, n (%) 2 (2.5%) 1 (6.2%) 1 (1.5%) 0.360
Laboratory parameters
Median IL-6 level, pg/mL (IQR) 24.5 (13.3–51.9) 93.8 (52.4–121.5) 18.0 (9.6–37.3) <0.001
Median CRP level, mg/dL (IQR) 3.0 (1.1–7.9) 8.7 (7.0–12.1) 2.3 (0.9–5.7) <0.001
Median LDH level, IU/L (IQR) 249 (203–329) 335 (285–484) 236 (193–300) <0.001
Median WBC count, ×103/mm3 (IQR) 5.6 (4.2–7.8) 8.3 (5.3–11.2) 5.1 (3.9–7.3) 0.003
Median D-dimer level, µg/mL (IQR) 0.7 (0.2–1.4) 0.9 (0.8–2.0) 0.5 (0.2–1.4) 0.048
Median Cr level, mg/dL (IQR) 0.8 (0.7–1.1) 1.1 (0.9–1.1) 0.8 (0.7–1.1) 0.027
Treatments
Invasive mechanical ventilation, n (%) 14 (17.3%) 13 (81.2%) 1 (1.5%) <0.001
Supplemental oxygen, n (%) 25 (30.9%) 3 (18.8%) 22 (33.8%) 0.370
Dexamethasone, n (%) 63 (77.8%) 16 (100%) 47 (72.3%) 0.017
Favipiravir, n (%) 53 (65.4%) 9 (56.2%) 44 (67.7%) 0.400
Median time from symptom onset to
admission, days (IQR) 4 (2–7) 7 (5–7) 4 (2–6) 0.020
Median time from symptom onset to the first
measurement of blood samples, days (IQR) 6 (4–9) 7 (6–10) 5 (3–9) 0.030
Prognosis
Survivors, n (%) 76 (93.8%) 13 (81.2%) 63 (96.9%) 0.050
Non-survivors, n (%) 5 (6.2%) 3 (18.8%) 2 (3.1%)
FiO2, fraction of inspiratory oxygen; BMI, body mass index; SD, standard deviation; IQR, interquartile range; IL-6, interleukin-6; CRP,
C-reactive protein; LDH, lactate dehydrogenase; WBC, white blood cell; Cr, creatinine.
Because dexamethasone administration could be a significant confounding factor,
a subgroup analysis focused on patients who received dexamethasone therapy. The 63 pa-
tients who received dexamethasone 6 mg daily were divided into 2 subgroups based on
whether dexamethasone administration was initiated before or after the laboratory values
were measured. A total of 28 patients received dexamethasone before the laboratory values
were measured (preceding group). The remaining 35 patients were administered dexam-
ethasone after the laboratory values were assessed (followed group). There were 10 and
6 patients assigned to the HFG in the preceding and followed groups, respectively. More
patients in the HFG group received invasive mechanical ventilation in both the preceding
and followed groups. No significant difference in the median time from symptom onset to
dexamethasone therapy was found between the HFG and LFG groups (Table 2).
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Table 2. Clinical characteristics between the two groups in the patients who received dexamethasone before or after
measurement of blood markers.
Preceding Dexamethasone
Maximum FiO2 ≥ 0.4 p-Value
Following Dexamethasone
Maximum FiO2 ≥ 0.4 p-Value
Yes (n = 10) No (n = 18) Yes (n = 6) No (n = 29)
Median IL-6 level, pg/mL (IQR) 97.3 (58.1–144.0) 13.6 (4.9–27.3) <0.001 79.2 (48.5–106.5) 31.7 (17.2–45.0) 0.054
Median CRP level, mg/dL (IQR) 7.4 (6.8–12.5) 2.7 (1.6–7.4) 0.018 9.9 (8.3–11.4) 3.0 (1.1–5.7) 0.023
Median LDH level, IU/L (IQR) 325 (263–455) 267 (210–349) 0.084 408 (301–585) 234 (199–270) 0.003
Median WBC count, ×103/mm3 (IQR) 10.5 (6.1–12.6) 7.5 (6.4–9.9) 0.204 6.2 (4.7–8.3) 4.9 (4.0–6.3) 0.220
Median D-dimer level, µg/mL (IQR) 1.0 (0.8–2.9) 1.1 (0.4–1.8) 0.360 0.8 (0.4–1.0) 0.3 (0.1–1.2) 0.342
Median Cr level, mg/dL (IQR) 1.0 (0.8–1.1) 0.8 (0.8–1.1) 0.401 1.1 (1.1–1.2) 0.9 (0.7–1.1) 0.069
Invasive mechanical ventilation, n (%) 7 (70.0%) 0 (0.0%) <0.001 6 (100%) 1 (3.4%) <0.001
Supplemental oxygen, n (%) 3 (30.0%) 11 (61.1%) 0.236 0 (0.0%) 10 (34.5%) 0.152
Median time from onset to
dexamethasone, days (IQR) 3.5 (2.0–5.0) 5.5 (3.0–10.0) 0.111 6.5 (6.0–8.5) 7.0 (5.0–8.0) 0.581
FiO2, fraction of inspiratory oxygen; IQR, interquartile range; IL-6, interleukin-6; CRP, C-reactive protein; LDH, lactate dehydrogenase;
WBC, white blood cell; Cr, creatinine.
3.2. Laboratory Markers in COVID-19 Patients with Respiratory Failure
First, among all patients, the levels of IL-6, CRP, LDH, WBC, D-dimer, and Cr in blood
specimens of the HFG and LFG patients were compared. As shown in Table 1, the values
of IL-6, CRP, LDH, WBC, D-dimer, and Cr were significantly higher in the HFG than
in the LFG patients. To assess the diagnostic value of these parameters for respiratory
failure with maximum FiO2 ≥ 0.4 within three days from laboratory measurement, ROC
analysis was performed. The AUC value of IL-6, CRP, and LDH was high value of 0.85
[0.74–0.97], 0.82 [0.71–0.92], and 0.81 [0.70–0.92] with the cutoff value of 43.9, 5.7, and 268,
respectively (Table 3). Among all patients, the OR value of each marker for the optimal
cutoff value was evaluated. The crude OR of IL-6, CRP, and LDH showed the high value of
29.1 [5.6–295.6], 18.9 [3.8–188.4] and 9.5 [2.3–57.4], respectively (Table 4). That value of Cr
showed no significance.
Second, among the patients who received preceding dexamethasone, the values of
each laboratory marker for predicting respiratory failure were compared between HFG and
LFG. IL-6 and CRP levels were significantly higher in the HFG than in the LFG (Table 2).
Considering that the dexamethasone therapy may affect respiratory condition, the adjusted
OR for each dexamethasone group was evaluated. The values of IL-6 and CRP adjusted for
preceding dexamethasone were 53.9 [4.5–3242.8] and 16.1 [1.6–847.9], respectively (Table 4).
The OR value of IL-6 and CRP adjusted for followed dexamethasone therapy showed
the same value (Table 4). The adjusted OR value of WBC, D-dimer, and Cr showed no
significance (Table 4).
Table 3. Diagnostic characteristics of each marker to predict respiratory failure within three days from the measurement of
these marker values.







IL-6 level (pg/mL) 0.85 (0.74–0.97) <0.001 43.9 87.5 (61.7–98.4) 81.5 (70.0–90.1) 53.8 (33.4–73.4) 96.4 (87.5–99.6)
CRP level (mg/dL) 0.82 (0.71–0.92) <0.001 5.7 87.5 (61.7–98.4) 73.8 (61.5–84.0) 45.2 (27.3–64.0) 96.0 (86.3–99.5)
LDH level (IU/L) 0.81 (0.70–0.92) <0.001 268 81.2 (54.4–96.0) 69.2 (56.6–80.1) 39.4 (22.9–57.9) 93.8 (82.8–98.7)
WBC count (×103/mm3) 0.74 (0.61–0.87) <0.001 7.8 56.2 (29.9–80.2) 81.5 (70.0–90.1) 42.9 (21.8–66.0) 88.3 (77.4–95.2)
D-dimer level (µg/mL) 0.66 (0.52–0.80) 0.023 0.7 81.2 (54.4–96.0) 58.5 (45.6–70.6) 32.5 (18.6–49.1) 92.7 (80.1–98.5)
Cr level (mg/dL) 0.68 (0.54–0.82) 0.012 0.9 66.7 (41.0–86.7) 58.5 (45.6–70.6) 30.8 (17.0–47.6) 86.4 (72.6–94.8)
IL-6, interleukin-6; CRP, C-reactive protein; LDH, lactate dehydrogenase; WBC, white blood cell; Cr, creatinine; AUC, area under the curve;
CI, 95% confidence interval; PPV, positive predictive value; NPV, negative predictive value.
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Table 4. The odds ratio of each marker for all patients and adjusted for preceding and followed dexamethasone therapy.
Whole Preceding Dexamethasone Followed Dexamethasone
Variable Crude OR (CI) p-Value Adjusted OR(CI) p-Value
Adjusted OR
(CI) p-Value
IL-6 29.1 (5.6–295.6) <0.001 53.9 (4.5–3242.8) <0.001 12.1 (1.1–646.6) 0.019
CRP 18.9 (3.8–188.4) <0.001 16.1 (1.6–847.9) 0.006 12.1 (1.1–646.6) 0.019
LDH 9.5 (2.3–57.4) <0.001 2.3 (0.4–18.0) 0.434 ∞ (2.3–∞) <0.001
WBC 5.5 (1.5–21.5) 0.004 2.8 (0.4–22.5) 0.254 4.1 (0.3–50.0) 0.195
D-dimer 6.0 (1.5–35.8) 0.005 5.4 (0.5–285.8) 0.194 3.6 (0.4–47.0) 0.191
Cr 2.8 (0.8–10.2) 0.068 4.4 (0.7–36.5) 0.114 3.4 (0.32–180.4) 0.377
IL-6, interleukin-6; CRP, C-reactive protein; LDH, lactate dehydrogenase; WBC, white blood cell; Cr, creatinine; OR, odds ratio; CI, 95%
confidence interval.
Additionally, because our study aimed to evaluate the predictive ability of blood
markers for respiratory deterioration within three days from analysis of these values,
the cutoff point of IL-6, CRP, and LDH at which the value of PPV was the highest was
determined. The cutoff value of IL-6 showed 91.5 with the corresponding PPV of 75.0%
[42.8–94.5] (Table 5). The PPV value of CRP and LDH with the cutoff point of 6.7 and 305
was 50.0% [29.9–70.1] and 42.3% [23.4–63.1], respectively (Table 5).
Table 5. The cutoff value of three inflammatory markers with the highest positive predictive value.
Variable Cutoff Sensitivity (%) (CI) Specificity (%) (CI) PPV (%) (CI) NPV (%) (CI)
IL-6 level (pg/mL) 91.5 56.2 (29.9–80.2) 95.4 (87.1–99.0) 75.0 (42.8–94.5) 89.9 (80.2–95.8)
CRP level (mg/dL) 6.7 81.2 (54.4–96.0) 80.0 (68.2–88.9) 50.0 (29.9–70.1) 94.5 (84.9–98.9)
LDH level (IU/L) 305 68.8 (41.3–89.0) 76.9 (64.8–86.5) 42.3 (23.4–63.1) 90.0 (80.0–97.0)
IL-6, interleukin-6; CI, 95% confidence interval; PPV, positive predictive value; NPV, negative predictive value.
Furthermore, to reinforce the correlation between these blood markers and respira-
tory failure, the SpO2/FiO2 ratio was calculated as a respiratory functional parameter.
As SpO2/FiO2 ratio would decrease by respiratory deterioration, the minimum value of
SpO2/FiO2 ratio within three days from laboratory measurement was selected for the cor-
relation analysis. Among the whole patients, the correlation coefficient value of CRP was
higher than that of IL-6. For the preceding dexamethasone group, that value was higher
in IL-6 than CRP (Figure 2).
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Figure 2. The correlation between minimum SpO2/FiO2 ratio and each blood marker: (a) IL-6 and (b) CRP among all
patients; (c) IL-6 and (d) CRP in the preceding dexamethasone group. SpO2, percutaneous oxygen saturation; FiO2, fraction
of inspired oxygen; IL-6, interleukin-6; CRP, C-reactive protein.
4. Discussion
Similar to recent studies, our data showed that IL-6, CRP, LDH, WBC, and D-dimer
levels were associated with the severity of COVID-19 infection within three days, which
were significantly elevated in HFG compared with that in LFG. In the context of critical
COVID-19 infection as multiple organ disease caused by cytokine response. Terpos et al.
mentioned that high D-dimer levels might be associated with lethal disseminated intravas-
cular coagulation (DIC)-related complications other than ARDS [5]. The WBC generally
increases according to acute inflammation; this may reflect pulmonary and extrapulmonary
organ damage, including respiratory distress, acute cardiac injury, and acute kidney injury.
The high Cr levels directly indicate kidney injury. The severity of the disease might influ-
ence LDH levels because LDH is a general indicator of acute or chronic tissue damage that
occurs in the heart, liver, lungs, muscles, and kidneys at high levels [2]. Our study revealed
the high correlation coefficients of the serum level of IL-6 and CRP to minimum SpO2/FiO2
ratio, demonstrating that increase of the two markers indicates respiratory failure within
three days after laboratory measurement. To find out the practical cutoff of these markers
for respiratory failure, we set the outcome of this study on oxygen requirement with maxi-
mum FiO2 ≥ 0.4. The ROC analysis showed the high AUC and OR value of both IL-6 and
CRP in the whole group. IL-6 level would be most useful with the highest value of AUC
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and the significant value of OR. In sub-group analysis, it was conspicuous that the median
IL-6 level was high in the HFG patients of the preceding dexamethasone group. It can
be explained by that this group might include a larger number of critical patients with
respiratory collapse, causing earlier demand for dexamethasone therapy. The introduc-
tion of the dexamethasone therapy was decided by clinical physicians based on patients’
respiratory conditions and oxygen requirements. The dexamethasone therapy itself may
not influence IL-6 level, which is supported by an analysis of the transcriptomic data that
indicates the therapeutic mechanism of dexamethasone in severe COVID-19 patients does
not involve IL-6 pathway [6]. The OR value of IL-6 adjusted for preceding dexamethasone
administration showed a high value, indicating that IL-6 levels might reflect an ongoing
respiratory deterioration in COVID-19 patients even under the dexamethasone therapy.
On the contrary, previous reports have demonstrated that IL-6 receptor inhibitor therapy,
such as tocilizumab, could prompt IL-6 synthesis to spike by receptor blockage [7]. Because
our study excluded the cases with that therapy, the cutoff values of our result should not
be applied to assess respiratory condition under IL-6 receptor inhibitor therapy.
Herold et al. demonstrated that elevated IL-6 levels predicted the need for mechanical
ventilation [8]. IL-6 was found to be a precise marker for predicting respiratory illness,
which is consistent with the highest OR in our study. As a result of this study, the optimal
cutoff value of 43.9 for IL-6 showed the highest NPV of 96.4% [87.5–99.6]. Another possible
cutoff value of IL-6 was 91.5, with the highest PPV of 75% [42.8–94.5]. These values of
IL-6 might be used for classification of COVID-19 patients according to their prospective
respiratory condition in the short term, for example, with a higher value of IL-6 than 91.5
for the respiratory deterioration group and a lower value of IL-6 than 43.9 for the stable
group. However, it should be noted that the focus of our study was a respiratory condition
within three days after assessing the laboratory data and that too early a decision on
medical intervention by these markers may not be recommended. The evaluation of these
biochemical markers requires appropriate subject and timing of the sample assessment and
modification by physical parameters in the clinical context of COVID-19.
Our results suggest that IL-6, which is the key cytokine located upstream of the inflam-
matory cytokine cascade, increases prior to ARDS in critical COVID-19 patients, followed
by an increase in acute-phase protein levels, such as CRP [9,10]. SARS-CoV-2 can rapidly
activate pathogenic Th1 cells to secrete pro-inflammatory cytokines such as granulocyte-
macrophage colony-stimulating factor (GM-CSF) and IL-6 [11]. The transition from viral
pneumonia to ARDS is abrupt and recognizing potentially worsening patients among
the stable majority must be a clinically urgent issue. Monitoring IL-6 as an early inflamma-
tory marker for ARDS can be a useful tool for identifying collapsing patients in preparation
for adequate interventions, particularly in pandemics with limited medical supplies.
A cytokine storm causing critical respiratory distress in COVID-19 is an immune
disease characterized by high-level activation of immune cells and excessive production
of massive inflammatory cytokines and chemical mediators [12]. Therefore, it has been
suggested that the blockade of inflammatory cytokines in COVID-19 patients is a possible
therapeutic tool. In clinical settings, many anti-inflammatory drugs, such as corticosteroids
and IL-6 receptor inhibitors, are candidates for therapeutic strategies against COVID-
19. However, the optimal timing for the administration of these drugs remains unclear.
Too early administration can adversely lead to a decrease in viral clearance [13]. The use of
corticosteroids has detrimental effects on the survival of patients not requiring oxygen [14].
IL-6 plays an important role in lung repair responses following viral insults, which means
that the timing of administration of IL-6 receptor inhibitors could affect proper tissue
remodeling [15]. Therefore, although the indication for medical interventions, including
anti-inflammatory drugs administration, should not be based solely on IL-6 levels, this
reliable marker could help physicians to judge appropriate timing for interventions.
Recently, in Japan, out-of-hospital sudden death during home recuperation owing
to COVID-19 pandemic is an emerging problem. The analysis for the COVID-19 patients
dying at home or in a hotel for recuperation showed that the duration from COVID-19
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diagnosis to death was 1–10 days (mean four days, median three days) [16]. Therefore,
evaluating the IL-6 levels might contribute to the adequate decision on whether the patient
should be admitted to hospital or not and subsequently to prevent out-of-hospital death.
This study had several limitations. First, this study was a single-center, retrospective
observational study; thus, the number of cases was small, and other confounding factors
might not have been considered. Second, since only six markers of blood specimens were
measured, more sensitive markers that reflect inflammatory conditions may not be realized.
Third, FiO2 was used as the parameter of the respiratory condition instead of the partial
pressure of oxygen in arterial blood (PaO2). Although the PaO2/FiO2 (p/F) ratio might be
more accurate for evaluating respiratory conditions, arterial blood gas analysis was not
undertaken for all patients in this study. Finally, high-flow oxygen with FiO2 ≥ 0.4 was
defined as respiratory failure, which might be the initial stage for acute respiratory distress.
5. Conclusions
The serum level of IL-6 is highly predictive of respiratory failure within three days
in COVID-19 patients. Further studies are needed to investigate the validity of this inflam-
matory marker for predicting respiratory illness associated with COVID-19.
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